Your position:www.healthoo.com >> EN >> EN >> Formulation >> Amgen to present results from phase 4 FOREMOST study of Otezla to treat early oligoarticular psoriatic arthritis at ACR 2023 >> article
 
Amgen to present results from phase 4 FOREMOST study of Otezla to treat early oligoarticular psoriatic arthritis at ACR 2023
Editor:xuezhe     Clicks:47    Date:2023-11-9 15:38:49
Keyword: ACR
Healthoo Information:
Amgen to present results from phase 4 FOREMOST study of Otezla to treat early oligoarticular psoriatic arthritis at ACR 2023
After registration, we will provide the sample reports and the more comprehensive consulting services for you.
UserName 
Contact:  Title: Mr.Ms.
Password  
Repeat password: 
Mobile 
Email 
Verification code: 
Company Name 
 
 E-mail:xuezhe@healthoo.com
 Tel.:86-10-68032463
  Our services:
 China Im\Ex data service
 Service fees of Chinese Vision
 Our service items
Online information introduction
Monthly information
Relative Information
  • Reasons for the sales growth of macrolides in Guo Bang Pharmaceutical ...
  • Analysis of 70 macrocyclic drugs approved by the FDA
  • Market Analysis of Macrolide Raw Materials
  • Indian import volumes of Macrolides in Jan. 2021
  • Import volumes of Macrolides APIs in India in Jul 2020
  • India import statistics of Macrolide APIs
  • Macrolides drugs rank in sample drugstores in March 2020
  • Hisun got Piracetam CEP certificate of Tacrolimus
  • HEC outputs of macrolide antibiotics in 2018
  • Macrolides export volumes in Jan-Sep 2018
  • Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
    Tel:+86-10-68032463